Our aim to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Pharmacy and Pharmaceutical Sciences.
To provide a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent solutions adopted in the fields of Pharmacy and Pharmaceutical Sciences.
August 28, 2021
Early Bird Registration
April 25 , 2021
November 15-17, 2021
On behalf of the Organization and Advisory Committee we take great pleasure and honor to invite all Doctors, Professors, Researchers, Students, other Faculty members, Academicians, Pharmacists, Experts and Scientists from the Pharmacy and Pharmaceutical fields to Luxembourg City, Luxembourg for the Global Conference on Pharmacy and Pharmaceutical Sciences to create an opportunity of global exchange of information on technological advances and new scientific innovations by contributing scientific research and expertise.
Global Conference on Pharmacy and Pharmaceutical Sciences (GCPP-2021) which will be held during November 15-17, 2021 in Luxembourg City, Luxembourg features three days of technical and scientific sessions, The event will have 5-6 world level (Highly cited class), Plenary speakers, established Keynote speakers, active Invited speakers. This meeting will offer you special opportunities to network with the pharmacy scientists, professors, researchers and experts of application fields across Europe and beyond.
The primary goal of GCPP-2021 is to promote the latest advancements, research, and developments, explore the challenges in Pharmacy and Pharmaceutical Science and connected areas. Take a chance and make it count in your Professional life.
We look forward to seeing you at Luxembourg on November, 2021
Why to Attend???
Who Should Attend and Who You’ll Meet
Directors/Senior Directors/Executive Directors, CEO’s, Presidents/Vice Presidents, Heads/Leaders, Partners, Research Associates, Research Scientist of Pharmacy, pharmaceutical, biomedical, biopharmaceutical and medical devices industries
Deans, Professors/ Associate Professors/ Assistant Professors, Research Scholars, Scientists and Students related to Pharmacy.
Guidelines for the Abstract Submission:
University of MaltaEurope
Anthony Serracino Inglott is a Professor at the Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta. Professor Serracino Inglott studied Pharmacy at the University of Malta and is a registered pharmacist. He continued his postgraduate studies at the University of Cincinnati where he obtained a Doctorate degree in Pharmacy and completed a residency at the University of Cincinnati Medical Centre. Serracino Inglott published over one hundred scientific papers and delivered a number of presentations at international conferences related to the pharmaceutical and regulatory sciences. Serracino Inglott’s consultancy experience includes being a court expert in toxicology and forensic sciences, advisory roles to Ministries and government entities, as well as Qualified Person for the pharmaceutical industry. He is Chairman of the Malta Laboratories Network and member within the Ethics Committee, Faculty of Medicine and Surgery and the board of governors of the Malta Competition and Consumer Affairs Authority. Since 2013, Professor Anthony Serracino Inglott is the Chairperson of the Malta Medicines Authority.
Prof. Dr. Guertin has 30+ years of experience as a researcher in neurosciences and 19 years of experience in science leadership. He is a serial entrepreneur who was founder and CEO of NeuroSpina Therapeutics between 2005 and 2008 as well as CSO of Eurymedon HealthCare during the same period. Afterward, he co-founded and acted for 8 years as CEO of Nordic Life Science Pipeline, a biopharma company focussing on the development and commercialization of next-generation pharmaceutical, healthcare and skincare products specifically designed for people with mobility impairment, paralysis and/or chronic diseases related to aging. To pursue clinical development activities (phase IIb trials) in Europe, he recently founded also Biosynergis Pharma (Wiltz, Luxembourg). He received a B.Sc. degree in 1989 (kinesiology) from University of Montréal, a M.Sc. degree in 1992 (neurokinetic) from University of Québec in Montréal, and a Ph.D. degree in 1996 (neurophysiology) from the University of Manitoba. He then pursued his training as a postdoctoral fellow between 1996 and 2000 in neuropharmacology (Copenhagen University), neurophysiology (University of Oxford), neurogenetics (University Aix-Marseille), and behavioral neurosciences (University of Montréal). He held also positions as a Professor (tenured since 2012) in the department of psychiatry & neurosciences (Laval University, 2001 – 2020, currently retired) as well as director and principal investigator of the Spinal Cord Injury and Functional Recovery Laboratory (2001 – 2020, Laval University Medical Center/CHU de Quebec). As a leading scientist, he is author and co-author of more than 175 publications (articles, reviews, book chapters, patents, etc.), acts as editorial board member for 32 international journals, and as referee/reviewer for the Canadian Institutes of Health Research, Natural Sciences & Engineering Research Council, and Fonds de Recherche du Québec. Among several breakthrough findings made in his laboratory since 2001, his main accomplishment remains undoubtedly the discovery in 2004/05 and the development from bench-to-clinical trials of the first oral drug ever, SpinalonTM, capable of reactivating spinal locomotor neurons and eliciting basic walking-like activity in paralyzed animals and patients with spinal cord injuries.
Temple University School of PharmacyUSA
Prof. Dr. Frank Breve is a Clinical Pharmacist Consultant at Baxter Healthcare Renal Division, President and CEO for Mid Atlantic PharmaTech Consultants, LLC and Opioid Consulting Educational Solutions, NPC at Ventnor City, NJ, USA. He is an Adjunct Clinical Assistant Professor at Temple University School of Pharmacy and Instructor for P142: Social and Economic Aspects of Healthcare, Department of Pharmacy Practice. He is a President for New Jersey Pharmacists Association. He did his Doctorate in Pharmacy at University of Colorado School of Pharmacy, MBA in Pharmaceutical Marketing at Saint Joseph’s University, BS in Pharmacy Temple University School of Pharmacy, BA in Psychology Temple University College of Liberal Arts, and Certified Consultant Pharmacist at Rutgers University. He received Bowl of Hygeia Award from American Pharmacists Association, Zammarelli Outstanding Lecturer Award from Temple University School of Pharmacy, Donald J. Wernik Academic Achievement Award from New Jersey Pharmacists Association and many more. He is also a professional member for many organizations and associations. His skilled areas are into Medicine, Benchmarking, Healthcare Consulting, Process Improvement, Quality Assurance, Medication Therapy Management, Clinical Development, Program Management, Long-term Care, Managed Care, Healthcare Management, Health Policy, Neuroscience, Pain Management, Pharmaceutics.
Jayoti Vidyapeeth Woman UniversityIndia
Dr. Anurekha Jain is presently a community awareness expert, social entrepreneur, CEO & Academician. She had worked as a Professor as well as Research Associate in TIFAC-Center of Relevance and Excellence in Green Pharmacy under the Ministry of Science & Technology, Government of India, for 13 years at B. R. Nahata College of Pharmacy. Later on, Dr. Jain worked as a Principal at the same college for two years. Prof Jain is presently working as a dean in the Dept of Pharmaceutical sciences at Jayoti Vidyapeeth Woman University, Jaipur Rajasthan. Dr. Jain is also working as a director for Innovare academic sciences Pvt. Ltd for online education, Intellectual property rights services, and research publication. Her fundamental research interest includes working in the field of Pharmaceuticals as well for the environment. She is the recipient of IDMA's best paper award, and she was overwhelmed when AICTE, DST & MAPCOST all proposed to fund her research presentation travel to France & Nepal. Dr. Jain published over 100 papers ( 36 international and 35 national papers) and 22 review articles, five books. And completed 02 Govt. projects, attended more than 52 conferences/workshops, applied for 04 patents and 04 industrial consultancy work, Organized 4 Govt. sponsored national seminars, and supervised 40 postgraduate theses along with 04 Ph.D. theses. Dr. Jain Recently visited Jakarta & Bali Four times as an invited speaker at Indonesia University. Dr. Jain is a founder of one NGO named Anokhi care to protect the environment, health awareness, and skills development. NGO works on developing some eco-friendly products like reusable cloth sanitary pads and mud sanitary pads incinerator/Vending machine/Fruit bioenzyme& cow urine-based disinfectant. She is currently involved in facilitating workshops on sustainable menstruation and menstrual hygiene as a community pharmacist and taught 2000 women and girls in the community, distributed cloth pads to the girls. She is also associated with girls' orphanage to develop their skills for employability and self-dependent. For Pad Stitching, she gives the women training, so employability saves health and the environment from the disposable pads. She got two social awards for out of box activity and declared as PAD women of Mandsaur District. Recently developed a Miyawaki forest and can give training to others for Miyawaki afforestation.
University of NebraskaUSA
Dr. Ally Dering-Anderson, BA, Pharm D, RP, FAPhA, is a Clinical Associate Professor in the Department of Pharmacy Practice & Science at the University of Nebraska-College of Pharmacy. She coordinates and teaches the Law & Ethics Classes, the OTC & Self Care Products Course, the Point-of-Care Testing Course, and the Immunization Course. She is also the preceptor for a Public Policy experiential rotation for senior level pharmacy students. A pharmacist immunization advocate, she has given more than 50,000 immunizations during her career. She was the 2015 Teacher of the Year for the College of Pharmacy and was named a Fellow in APhA in 2017. Ally served as the 2019 President of the Nebraska Pharmacists Association. Ally is a graduate of Doane College in Crete, Nebraska and the University of Nebraska -College of Pharmacy. She has been a licensed and practicing pharmacist in Nebraska and Iowa for over 30 years. She served as the Assistant Executive Director of the Nebraska Pharmacists Association for 13 years and worked the “vampire shift” for Walgreens. She has spoken nationally and internationally on pharmacy topics.
Harvard Medical SchoolUSA
Dr. Wu is an associate professor at Dermatology Department, Massachusetts General Hospital, Harvard Medical School (HMS). She received her Ph.D. from Utah State University and did her postdoctoral training at the Massachusetts Institute of Technology (MIT) and HMS. She has authored over 100 publications and her research has been continuously funded for two decades by various competitive funds from the National Institutes of Health (NIH), Department of Defense, the American Cancer Society, the Crohn’s & Colitis Foundation of America, the American Heart Association, etc. She is frequently invited to give talks in national and international conferences and serves as conference chair, a member of the organizing committee, and section-chair or co-chair of several international meetings including the International Society for Optics and Photonics. Research interests in Dr. Wu’s lab are the development of nanoparticle-based adjuvants for universal influenza vaccines, needle-free, pain-less, lesion-free delivery of drugs and vaccines, microneedle-based immune therapy for food allergy, and antimicrobial activity of blue light combined with ingredients of edible oils in preclinical studies. In addition, her team is the pioneer in using infrared light to accelerate platelet regeneration, in the development of laser-mediated vaccine adjuvant, and in selective microvasculature leakage for measuring various circulating biomarkers by probe-specific microneedle arrays without drawing any blood.
Dr. Anka G. Ehrhardt is a biophysicist with a doctorate degree in human physiology. Throughout her career, Dr. Ehrhardt combined scientific and technical expertise with strategic excellence and operational savvy to build and run laboratories and teams, design, implement, and run clinical studies, drive them to become Centers of Excellence and key partners, serving the discovery and development needs of large biopharmaceutical companies and patient-need-focused organizations. Through her work at Merck & Co., Inc. and Bristol Myers Squibb, Dr. Ehrhardt encountered the key issues in biopharma research and development; and demonstrated the power and success of strategic planning and analysis. Based on observed needs, Dr. Ehrhardt built and lead teams of increasing size in developing and implementing strategies, contributing to the discovery and development of over 50 key leads and drugs. In 2017, Dr. Ehrhardt joined CHDI Management, Inc., where she is directing international clinical studies and clinical biomarker research. Dr. Ehrhardt is currently on the board of different industry organizations, fostering innovation and collaboration between industry, academia and government organizations.
Dr. Karin E. Peuschel studied medicine and molecular biology at the University of Zurich (Switzerland), she completed her medical thesis at the University of Zurich, followed by work in different clinical specialties and molecular biology and completion of a residency in psychiatry and psychotherapy. She is currently the head of Praxis Erlenhof in Zug (Switzerland) and independent researcher in psychiatry and psychotherapy. She has published in the field of molecular biology, pharmacology, psychiatry and psychotherapy and has been serving as a reviewer, speaker and an organizing committee member. She has published papers concerning the indirect antiviral activity of Propranolol, in prion research, concerning the mechanism of hemochromatosis, a novel megaprimer PCR and a novel annealing equation of nucleic acids. She has developed a novel psychotherapy of addictive disorders, of dissociation, psychosomatic symptoms, subconscious defense mechanisms and psychogenic pain.
Prof. Dr. Nahlah Elkudssiah Ismail graduated with a Bachelor's Degree in Pharmacy (Hons) from Universiti Kebangsaan Malaysia in the year 2000 with Pharmacy Board of Malaysia registration in 2001. Prof. Dr. Nahlah successfully awarded a PhD degree (Distinction Report) in the field of clinical pharmaceutics at the Institute of Pharmaceutical Innovation (IPI) and School of Pharmacy, University of Bradford, Bradford, United Kingdom (UK) in July 2005. To date, she has taught more than 75 courses to diploma, degree and postgraduate students in United Kingdom and Malaysia using innovative teacher- and student-centered learning. As the pioneer of clinical pharmaceutics in Malaysia, she is the founder of the first Clinical Pharmaceutics Research Group (CPRG) (2008) in Malaysia and that was later acknowledged as Clinical BioPharmaceutics Research Group (CBRG) under Research Initiative Group (RIG) by Research Management Institute (RMI), Universiti Teknologi MARA (UiTM), Malaysia. The CBRG comprised of Inhalational Delivery Lab (IDL), Biomedical Analysis Lab (BAL), and Honey Research Lab. IDL was the first in Asia comprising all pivotal facilities in analyzing particles deliveries emitted from various medical devices including nasal spray, metered-dose inhalers, spacers, dry powder inhalers, and various types of nebulizers, industrial and domestics sprays, as well as environmental air quality assessment ranging from nano to micro sizes of particles. Prof. Dr. Nahlah holds membership in various local and international pharmacy and health based organizations. She has been publishing more than 250 publications including research journal articles, proceedings, chapters in books, books, and magazines. She has been invited to deliver lectures, talks (keynote/plenary/distinguished speaker) and conduct workshops at local and international events as well as a reviewer and editorial board member for local and international journals, and serve organizing committee members in various conferences. The research area of interest mainly in the field of pharmaceutics (drug delivery; nanotechnology; inhalational deliveries), pharmaceutical analysis (method development, detection and validation), clinical pharmacy, pharmacy education and leadership, pharmacy practice, public health, neurobehavioural-psychosocial, pharmaceutical policy, complementary and alternative medicines. She is also actively participating in honey, plant, and animal modeling studies in exploring and defining new therapeutic entities. Prof. Dr. Nahlah had been awarded research and travel grants as well as awards and medals in national and international scientific invention, innovation and design exhibitions, competitions, conferences, and community services. As a senior clinical pharmacist and a teacher-practitioner, she was one of the regular invited guests for radio UFM Malaysia under segment “U & Health” covering numerous health topics as well as one of the invited speakers for leadership and soft skills development. She has been as the Chairman and member of Boards of Studies for Diploma in Pharmacy, Bachelor of Pharmacy (Hons), Master in Clinical Pharmacy, Master and PhD studies, involving heavily in curriculum review, audits, recognition and accreditation affairs. Holding various posts at different senior management levels at different institutions, currently, Prof. Dr. Nahlah is the Council Member of the Malaysian Academy of Pharmacy.
Dr. Sergey Suchkov graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his Ph.D. at the I.M. Sechenov Moscow Medical Academy and in 2001, maintained his Doctorship Degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute. Dr. Suchkov has been trained at: NIH; Wills Eye Hospital, PA, USA; University of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr. Sergey Suchkov is a Chair, Dept for Personalized and Translational Medicine, I.M. Sechenov First Moscow State Medical University. He is a member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); PMC (Personalized Medicine Coalition), Washington, USA.